Karyopharm Therapeutics Files Registration Statement for Proposed Initial Public OfferingNatick, Mass. – October 7, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Karyopharm. The number of shares to be offered and the price range for the offering have not yet been determined.
BofA Merrill Lynch and Leerink Swann LLC are acting as joint book-running managers for the offering. JMP Securities LLC and Oppenheimer & Co. are acting as co-managers.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold and offers to buy may not be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy and there shall not be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via e-mail at dg.prospectus_requests@baml.com, or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or via telephone at (800) 808-7525.
About Karyopharm
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company founded by Dr. Sharon Shacham and co-founded by Dr. Michael Kauffman focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm’s Selective Inhibitors of Nuclear Export (SINE) compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell, thereby leading to their accumulation in the nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. Karyopharm is located in Natick, Massachusetts.